The best method of renin-angiotensin-aldosterone system blockade in patients with hypertension and diabetes mellitus?

Czech version

Authors: J. Špác
Authors‘ workplace: II. interní klinika LF MU a FN U sv. Anny v Brně
Published in: Kardiol Rev Int Med 2016, 18(1): 13-16
Category: Cardiology Review

Motto: Metaanalýza je jako párek nebo klobása – nikdo, kromě řezníka, neví, co obsahuje.

Overview

The aim of this article is to evaluate the efficacy and safety of different methods of blockade of the renin-angiotensin-aldosterone system (RAAS) in patients with type 2 diabetes. It is not entirely clear how to best and most effectively block the RAAS system in diabetic patients due to the lack of data from randomised clinical trials. Knowledge about treatment methods in this group of patients is obtained only from subgroup analyses and metaanalyses, where results may be less reliable. Combination therapy with ACE inhibitors and ARBs could more effectively block the RAAS, but present findings demonstrate conflicting results, particularly as regards the safety of patients.

Keywords:
diabetes mellitus type 2. – hypertension – renin-angiotensin-aldosterone system

Sources

1. Ceconi C, Francolini G, Olivares A et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007; 577: 1– 6.

2. Crackower MA, Sarao R, Oudit GY et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822– 828.

3. Yusuf S, Teo KK, Pogue J et al. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547– 1559. doi: 10.1056/ NEJMoa0801317.

4. Lindholm LH, Ibsen H, Dahlöf B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004– 1010.

5. Julius S, Kjeldsen SJ, Weber M et al. The VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022– 2031.

6. Bangalore S, Kumar S, Wetterslev J et al. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147,020 patients from randomised trials. BMJ 2011; 342: d2234. doi: 10.1136/ bmj.d2234.

7. van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012; 33: 2088– 2097. doi: 10.1093/ eurheartj/ ehs075.

8. Savarese G, Constanzo P, Cleland JG et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patiens without heart failure. J Am Coll Cardiol 2013; 61: 131– 142. doi: 10.1016/ j.jacc.2012.10.011.

9. Špinar J, Vítovec J, Souček M. Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/ or NephropAthy (the MEDINA study). Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013; 158: 412– 421. doi: 10.5507/ bp.2013.053.

10. Ravid M, Land R, Rachmani R et al. Long term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7- year follow-up study. Arch Intern Med 1996; 156: 286– 289.

11. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253– 259.

12. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861– 869.

13. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851– 860.

14. Jandeleit-Dahm KA, Tikellis C, Reid CM et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463– 443.

15. Cheng J, Zhang W, Zhang X et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patiens with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014; 174: 773– 785. doi: 10.1001/ jamainternmed.2014.348.

16. Václavík J, Slíva J. Inhibitory ACE, nebo sartany v léčbě hypertenze: zbytečná diskuze. Cor Vasa 2014; 56: 477– 479.

17. Palmer SC, Mavridis D, Navarese E et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta analysis. Lancet 2015; 385: 2047– 2056. doi: 10.1016/ S0140-6736(14)62459-4.

18. Catala Lopez F, Macias Saint-Gerons D. Diabetes mellitus and risks of dual blockade of the renin-angiotensin-aldosterone system. Rev Esp Cardiol 2013; 66: 403– 415. doi: 10.1016/ j.rec.2012.11.010.

19. Susantitaphong P, Sewaralthahab K, Balk EM et al. Efficacy and safety of combined vs. single renin-angiotensin- aldosterone system blockade in chronic kidney disease: a meta-analysis. Am J Hypertens 2013; 26: 424– 441. doi: 10.1093/ ajh/ hps038.